Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12605000792628
Ethics application status
Approved
Date submitted
15/12/2005
Date registered
16/12/2005
Date last updated
16/12/2005
Type of registration
Retrospectively registered

Titles & IDs
Public title
First line irinotecan dose escalation study
Scientific title
Pilot study to assess safety and efficacy of a single implantation of SIR-Spheres plus systemic chemotherapy with 5-fluorouracil, leucovorin and irinotecan in patients with non-resectable liver metastases from primary adenocarcinoma of the large bowel
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic colorectal cancer 951 0
Condition category
Condition code
Cancer 1020 1020 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This multi-centre dose escalation study is designed to assess the safety and efficacy of a single implant of SIR-Spheres when given in combination with the first line chemotherapy combination consisting of irinotecan, 5-fluorouracil and leucovorin. The chemotherapy will be administered on weeks 1 and 2 of a 3 week cycle and given for 3 cycles. The irinotecan will then be escalated to the standard dose and an additional 6 cycles of chemotherapy will be administered.
Intervention code [1] 805 0
Treatment: Devices
Comparator / control treatment
Control group
Uncontrolled

Outcomes
Primary outcome [1] 1367 0
Toxicity
Timepoint [1] 1367 0
Assessed up to 1 month after the conclusion of protocol chemotherapy
Primary outcome [2] 1368 0
Response rate
Timepoint [2] 1368 0
Assessed up until the scan after the conclusion of protocol chemotherapy
Secondary outcome [1] 2419 0
Time to progressive disease
Timepoint [1] 2419 0
Secondary outcome [2] 2420 0
Site of progressive disease
Timepoint [2] 2420 0
Secondary outcome [3] 2421 0
Survival
Timepoint [3] 2421 0

Eligibility
Key inclusion criteria
Histologically confirmed primary adenocarcinoma of the large bowelCT evidence of metastases in the liverLiver metastases not treatable by some form of local ablation. Prior treatment with 5FU based chemotherapy permissible for the irinotecan alone armAdequate haematological, renal and hepatic functionWHO performance status 0-2Willing and able to provide written informed consent.
Minimum age
18 Years
Maximum age
Not stated
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Pregnant or breast feedingEvidence of ascites, cirrhosis or portal hypertension as determined by clinical assessmentCNS metastasesPrevious radiotherapy to the liverimmeasurable or unevaluable metastases to the liverHepatic arterial anatomy that will prevent administration of SIR-Spheres>20% atreriovenous lung shuntingTreatment with capecitabine within 8 weeks of SIRT.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/10/2001
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
12
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 1122 0
Commercial sector/Industry
Name [1] 1122 0
Sirtex Medical Limited
Country [1] 1122 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Sirtex Medical Limited
Address
Country
Australia
Secondary sponsor category [1] 980 0
None
Name [1] 980 0
None
Address [1] 980 0
Country [1] 980 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 2436 0
Mount Hospital
Ethics committee address [1] 2436 0
Ethics committee country [1] 2436 0
Australia
Date submitted for ethics approval [1] 2436 0
Approval date [1] 2436 0
Ethics approval number [1] 2436 0
Ethics committee name [2] 2437 0
Greenslopes Hospital
Ethics committee address [2] 2437 0
Ethics committee country [2] 2437 0
Australia
Date submitted for ethics approval [2] 2437 0
Approval date [2] 2437 0
Ethics approval number [2] 2437 0
Ethics committee name [3] 2438 0
Royal Adelaide Hospital
Ethics committee address [3] 2438 0
Ethics committee country [3] 2438 0
Australia
Date submitted for ethics approval [3] 2438 0
Approval date [3] 2438 0
Ethics approval number [3] 2438 0
Ethics committee name [4] 2439 0
Prince of Wales Hospital
Ethics committee address [4] 2439 0
Ethics committee country [4] 2439 0
Australia
Date submitted for ethics approval [4] 2439 0
Approval date [4] 2439 0
Ethics approval number [4] 2439 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35705 0
Address 35705 0
Country 35705 0
Phone 35705 0
Fax 35705 0
Email 35705 0
Contact person for public queries
Name 9994 0
Michael Tapner
Address 9994 0
Sirtex Medical Ltd
PO Box 760
North Ryde NSW 1670
Country 9994 0
Australia
Phone 9994 0
+61 2 99361426
Fax 9994 0
Email 9994 0
[email protected]
Contact person for scientific queries
Name 922 0
Dr Guy van Hazel
Address 922 0
Perth Oncology
Mount Medical Centre
146 Mounts Bay Road
Perth WA 6000
Country 922 0
Australia
Phone 922 0
+61 8 94813072
Fax 922 0
Email 922 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.